Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1-5 trials.

Aroda VR, Capehorn MS, Chaykin L, Frias JP, Lausvig NL, Macura S, Lüdemann J, Madsbad S, Rosenstock J, Tabak O, Tadayon S, Bain SC.

Diabetes Obes Metab. 2019 Oct 13. doi: 10.1111/dom.13896. [Epub ahead of print]

PMID:
31608552
2.

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators.

JAMA. 2019 Sep 19. doi: 10.1001/jama.2019.13772. [Epub ahead of print]

PMID:
31536101
3.

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.

Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators.

Diabetes Care. 2019 Sep 17. pii: dc190883. doi: 10.2337/dc19-0883. [Epub ahead of print]

PMID:
31530666
4.

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR.

Diabetes Care. 2019 Sep 17. pii: dc191357. doi: 10.2337/dc19-1357. [Epub ahead of print]

PMID:
31530665
5.

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.

Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE; CARMELINA Investigators.

Diabetes Care. 2019 Oct;42(10):1930-1938. doi: 10.2337/dc19-0783. Epub 2019 Aug 9.

PMID:
31399442
6.

Bringing closure: towards achieving a better understanding of Israel.

Rosenstock J, Zimmet P, Skyler JS, Atkinson M, Schatz D, Buse JB, Kahn S, Hirsch IB, Leroith D, Alberti KG.

Lancet. 2019 Aug 17;394(10198):559. doi: 10.1016/S0140-6736(19)31760-X. Epub 2019 Jul 31. No abstract available.

PMID:
31376991
7.

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.

Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KH.

Diabetes Care. 2019 Sep;42(9):1733-1741. doi: 10.2337/dc18-2648. Epub 2019 Jul 18.

PMID:
31320446
8.

Fibrillary Glomerulonephritis: An Update.

Rosenstock JL, Markowitz GS.

Kidney Int Rep. 2019 Apr 29;4(7):917-922. doi: 10.1016/j.ekir.2019.04.013. eCollection 2019 Jul. Review.

9.

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M; PIONEER 1 Investigators.

Diabetes Care. 2019 Sep;42(9):1724-1732. doi: 10.2337/dc19-0749. Epub 2019 Jun 11.

PMID:
31186300
10.

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.

Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, Pang C, Wood R, Kinduryte O, George JT, Marquard J, Soleymanlou N.

Diabetes Care. 2019 Sep;42(9):1716-1723. doi: 10.2337/dc19-0548. Epub 2019 Jun 8.

PMID:
31177179
11.

Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.

Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S.

Diabetes Obes Metab. 2019 Sep;21(9):2152-2162. doi: 10.1111/dom.13795. Epub 2019 Jun 24.

12.

Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.

Bergenstal RM, Peyrot M, Dreon DM, Aroda VR, Bailey TS, Brazg RL, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Ramtoola S, Rosenstock J, Serusclat P, Weinstock RS, Naik RG, Shearer DM, Zraick V, Levy BL; Calibra Study Group.

Diabetes Technol Ther. 2019 May;21(5):273-285. doi: 10.1089/dia.2018.0298. Epub 2019 Apr 26.

13.

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.

Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M; PIONEER 3 Investigators.

JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942.

14.

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P.

Diabetes Care. 2019 May;42(5):919-930. doi: 10.2337/dc18-2149. Epub 2019 Mar 4.

PMID:
30833371
15.

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT.

Diabetes Obes Metab. 2019 May;21(5):1073-1078. doi: 10.1111/dom.13645. Epub 2019 Mar 12.

PMID:
30690856
16.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
17.

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594. [Epub ahead of print]

18.

Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.

Menon V, Lincoff AM, Nicholls SJ, Jasper S, Wolski K, McGuire DK, Mehta CR, Rosenstock J, Lopez C, Marcinak J, Cao C, Nissen SE; GRAND 306 Investigators.

Diabetes Care. 2018 Dec;41(12):2603-2609. doi: 10.2337/dc18-0755.

PMID:
30459247
19.

A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.

Maloney A, Rosenstock J, Fonseca V.

Clin Pharmacol Ther. 2019 May;105(5):1213-1223. doi: 10.1002/cpt.1307. Epub 2019 Jan 13.

PMID:
30457671
20.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

21.

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.

Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL.

Arch Endocrinol Metab. 2018 Aug;62(4):424-430. doi: 10.20945/2359-3997000000056.

22.

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA.

Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4.

PMID:
30287422
23.

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.

Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB.

Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13.

PMID:
30104294
24.

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ.

Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13.

25.

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.

Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators.

Diabetes Obes Metab. 2018 Dec;20(12):2768-2777. doi: 10.1111/dom.13457. Epub 2018 Aug 7.

PMID:
29961998
26.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P.

Diabetes Care. 2018 Sep;41(9):1970-1980. doi: 10.2337/dc18-0343. Epub 2018 Jun 24.

27.

Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology.

Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L.

Diabetes Care. 2018 Jul;41(7):1327-1329. doi: 10.2337/dci18-0035. No abstract available.

PMID:
29934474
28.

Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.

Pratley RE, Rosenstock J, Heller SR, Sinclair A, Heine RJ, Kiljański J, Brusko CS, Duan R, Festa A.

J Diabetes Sci Technol. 2018 Nov;12(6):1184-1191. doi: 10.1177/1932296818776993. Epub 2018 Jun 12.

29.
30.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.

Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B.

Diabetes Obes Metab. 2018 Sep;20(9):2220-2228. doi: 10.1111/dom.13354. Epub 2018 Jun 5.

PMID:
29766635
31.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J.

Diabetes Obes Metab. 2018 Sep;20(9):2229-2237. doi: 10.1111/dom.13363. Epub 2018 Jun 10.

PMID:
29761615
32.

Prevalence of Proteinuria and Albuminuria in an Obese Population and Associated Risk Factors.

Rosenstock JL, Pommier M, Stoffels G, Patel S, Michelis MF.

Front Med (Lausanne). 2018 Apr 30;5:122. doi: 10.3389/fmed.2018.00122. eCollection 2018.

33.

Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.

Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J.

Diabetes Metab. 2018 Nov;44(5):402-409. doi: 10.1016/j.diabet.2018.02.002. Epub 2018 Feb 19.

34.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

35.

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.

Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J.

Diabetes Obes Metab. 2018 Jul;20(7):1602-1614. doi: 10.1111/dom.13266. Epub 2018 Mar 25.

36.

Self-Assessment of Teaching Skills Among Psychiatric Residents.

Spada M, Lundblad W, Glance J, Rosenstock J, Gopalan P, Azzam PN, Jacobson SL, Travis MJ.

Acad Psychiatry. 2018 Aug;42(4):477-481. doi: 10.1007/s40596-017-0877-z. Epub 2018 Feb 22.

PMID:
29473133
37.

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.

Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C.

Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25.

38.

Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.

Henry RR, Rosenstock J, Denham DS, Prabhakar P, Kjems L, Baron MA.

Diabetes Care. 2018 Mar;41(3):613-619. doi: 10.2337/dc17-1519. Epub 2018 Jan 4.

PMID:
29301824
39.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

40.

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.

Rosenstock J, Buse JB, Azeem R, Prabhakar P, Kjems L, Huang H, Baron MA.

Diabetes Care. 2018 Feb;41(2):333-340. doi: 10.2337/dc17-1306. Epub 2017 Dec 14.

PMID:
29242349
41.

Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.

Henry R, Rosenstock J, McCarthy JF, Carls G, Alessi T, Yee J, Baron M.

Diabetes Obes Metab. 2018 Mar;20(3):638-645. doi: 10.1111/dom.13133. Epub 2017 Nov 20.

PMID:
29053202
42.

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J.

JAMA. 2017 Oct 17;318(15):1460-1470. doi: 10.1001/jama.2017.14752.

43.

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).

Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG.

Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Erratum in: Diabetes Obes Metab. 2018 Nov;20(11):2708.

PMID:
28857451
44.

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program.

Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Review.

45.

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, George JT, Rosenstock J.

Diabetes Care. 2017 Sep;40(9):1144-1151. doi: 10.2337/dc17-0068.

PMID:
28830955
46.

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.

Wysham CH, Rosenstock J, Vetter ML, Dong F, Öhman P, Iqbal N.

Diabetes Obes Metab. 2018 Jan;20(1):165-172. doi: 10.1111/dom.13056. Epub 2017 Aug 22.

47.
48.

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J.

Diabetes Obes Metab. 2017 Dec;19(12):1798-1804. doi: 10.1111/dom.12980. Epub 2017 Jul 7.

49.

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.

Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L Trial Investigators.

Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. Epub 2017 Apr 20. No abstract available.

50.

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.

Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators.

Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06c. Epub 2017 Apr 18. No abstract available.

Supplemental Content

Loading ...
Support Center